The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Hepatitis B Virus (HBV) peptides. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Hepatitis B Virus (HBV) peptides is a key innovation area in pharmaceutical

HBV peptides represent peptides derived from the hepatitis B virus (HBV). These may serve as HLA class I-restricted T cell epitopes and can be used as an antigen-specific positive control to stimulate T cells. Vaccination with these peptides is a promising new treatment strategy for chronic HBV.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of Hepatitis B Virus (HBV) peptides.

Key players in Hepatitis B Virus (HBV) peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to Hepatitis B Virus (HBV) peptides

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Compagnie Merieux Alliance 62 Unlock Company Profile
Globeimmune 58 Unlock Company Profile
GSK 52 Unlock Company Profile
Kuros Biosciences 50 Unlock Company Profile
TheVax Genetics Vaccine 49 Unlock Company Profile
Melbourne Health 32 Unlock Company Profile
Yangshengtang 24 Unlock Company Profile
Advanced Biological Laboratories 24 Unlock Company Profile
Worg Pharmaceuticals Hangzhou 21 Unlock Company Profile
Green Cross Holdings 21 Unlock Company Profile
Biomay 21 Unlock Company Profile
Fastilium Property Group 21 Unlock Company Profile
F. Hoffmann-La Roche 19 Unlock Company Profile
iQur 18 Unlock Company Profile
Xiamen Innovax Biotech 17 Unlock Company Profile
Austin Health 17 Unlock Company Profile
Valneva 17 Unlock Company Profile
Academia Sinica 16 Unlock Company Profile
Westinghouse Air Brake Technologies 16 Unlock Company Profile
International Centre for Genetic Engineering and Biotechnology 15 Unlock Company Profile
Bharat Biotech 15 Unlock Company Profile
Gilead Sciences 15 Unlock Company Profile
Biomed Realty Trust 13 Unlock Company Profile
Southern Health 13 Unlock Company Profile
Biogen 12 Unlock Company Profile
PowderJect Vaccines 12 Unlock Company Profile
Johnson & Johnson 11 Unlock Company Profile
Altimmune 11 Unlock Company Profile
Cue Biopharma 11 Unlock Company Profile
HU Group Holdings 11 Unlock Company Profile
Dynavax Technologies 11 Unlock Company Profile
Precigen 10 Unlock Company Profile
Chimeros 10 Unlock Company Profile
Siemens 10 Unlock Company Profile
Proteome Sciences 10 Unlock Company Profile
Shanghai HEP Pharmaceutical 9 Unlock Company Profile
Endo International 9 Unlock Company Profile
St Vincent’s Health Australia 9 Unlock Company Profile
Gulftech International 9 Unlock Company Profile
ISA Pharmaceuticals 8 Unlock Company Profile
Lion TCR 8 Unlock Company Profile
Hualan Biological Engineering 8 Unlock Company Profile
Sanofi 8 Unlock Company Profile
German Cancer Research Center 8 Unlock Company Profile
Celltrion 7 Unlock Company Profile
Alfred Health Victoria 7 Unlock Company Profile
Japan Science and Technology Agency 7 Unlock Company Profile
SJ Biomed 7 Unlock Company Profile
Beacle 6 Unlock Company Profile
Catalent 6 Unlock Company Profile

Source: GlobalData Patent Analytics

Globeimmune is the leading patent filer in Hepatitis B Virus (HBV) peptides. It is focused on the treatment of cancer and infectious diseases based on proprietary Tarmogen platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production.

In terms of application diversity, Proteome Sciences is the top company, followed by Biogen and Chimeros. By means of geographic reach, Celltrion holds the top position, while Biomay and Catalent stand in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.